Buyck, Julien
[UCL]
Tulkens, Paul M.
[UCL]
Van Bambeke, Françoise
[UCL]
Antibiotic combinations are often used for treating Pseudomonas aeruginosa infections but their efficacy toward intracellular bacteria has not been investigated so far. We have studied combinations of representatives of the main antipseudomonal classes (ciprofloxacin, meropenem, tobramycin, and colistin) against intracellular P. aeruginosa in a model of THP-1 monocytes in comparison with bacteria growing in broth, using the reference strain PAO1 and two clinical isolates (resistant to ciprofloxacin and meropenem, respectively). Interaction between drugs was assessed by checkerboard titration (extracellular model only), by kill curves, and by using the fractional maximal effect (FME) method, which allows studying the effects of combinations when dose-effect relationships are not linear. For drugs used alone, simple sigmoidal functions could be fitted to all concentration-effect relationships (extracellular and intracellular bacteria), with static concentrations close to (ciprofloxacin, colistin, and meropenem) or slightly higher than (tobramycin) the MIC and with maximal efficacy reaching the limit of detection in broth but only a 1 to 1.5 (colistin, meropenem, and tobramycin) to 2 to 3 (ciprofloxacin) log10 CFU decrease intracellularly. Extracellularly, all combinations proved additive by checkerboard titration but synergistic using the FME method and more bactericidal in kill curve assays. Intracellularly, all combinations proved additive only based on both FME and kill curve assays. Thus, although combinations appeared to modestly improve antibiotic activity against intracellular P. aeruginosa, they do not allow eradication of these persistent forms of infections. Combinations including ciprofloxacin were the most active (even against the ciprofloxacin-resistant strain), which is probably related to the fact this drug was the most effective alone intracellularly.
- Sun Hsin-Yun, Fujitani Shigeki, Quintiliani Richard, Yu Victor L., Pneumonia Due to Pseudomonas aeruginosa, 10.1378/chest.10-0167
- Fish D. N., Synergic activity of cephalosporins plus fluoroquinolones against Pseudomonas aeruginosa with resistance to one or both drugs, 10.1093/jac/dkf211
- McGrath B J, Lamp K C, Rybak M J, Pharmacodynamic effects of extended dosing intervals of imipenem alone and in combination with amikacin against Pseudomonas aeruginosa in an in vitro model., 10.1128/aac.37.9.1931
- Cappelletty D. M., Kang S. L., Palmer S. M., Rybak M. J., Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model, 10.1128/aac.39.8.1797
- Bergen P. J., Tsuji B. T., Bulitta J. B., Forrest A., Jacob J., Sidjabat H. E., Paterson D. L., Nation R. L., Li J., Synergistic Killing of Multidrug-Resistant Pseudomonas aeruginosa at Multiple Inocula by Colistin Combined with Doripenem in an In Vitro Pharmacokinetic/Pharmacodynamic Model, 10.1128/aac.05298-11
- Bergen P. J., Forrest A., Bulitta J. B., Tsuji B. T., Sidjabat H. E., Paterson D. L., Li J., Nation R. L., Clinically Relevant Plasma Concentrations of Colistin in Combination with Imipenem Enhance Pharmacodynamic Activity against Multidrug-Resistant Pseudomonas aeruginosa at Multiple Inocula, 10.1128/aac.05028-11
- Gordon N. C., Png K., Wareham D. W., Potent Synergy and Sustained Bactericidal Activity of a Vancomycin-Colistin Combination versus Multidrug-Resistant Strains of Acinetobacter baumannii, 10.1128/aac.00922-10
- Miller M H, Feinstein S A, Chow R T, Early effects of beta-lactams on aminoglycoside uptake, bactericidal rates, and turbidimetrically measured growth inhibition in Pseudomonas aeruginosa., 10.1128/aac.31.1.108
- Buyck J. M., Tulkens P. M., Van Bambeke F., Pharmacodynamic Evaluation of the Intracellular Activity of Antibiotics towards Pseudomonas aeruginosa PAO1 in a Model of THP-1 Human Monocytes, 10.1128/aac.02609-12
- Lovewell R. R., Patankar Y. R., Berwin B., Mechanisms of phagocytosis and host clearance of Pseudomonas aeruginosa, 10.1152/ajplung.00335.2013
- Schmiedl Andreas, Kerber-Momot Tanja, Munder Antje, Pabst Reinhard, Tschernig Thomas, Bacterial distribution in lung parenchyma early after pulmonary infection with Pseudomonas aeruginosa, 10.1007/s00441-010-1036-y
- Boyd Natalie, Nailor Michael D, Combination Antibiotic Therapy for Empiric and Definitive Treatment of Gram-Negative Infections: Insights from the Society of Infectious Diseases Pharmacists, 10.1592/phco.31.11.1073
- Engel Joanne, Eran Yonatan, Subversion of Mucosal Barrier Polarity by Pseudomonas Aeruginosa, 10.3389/fmicb.2011.00114
- Nguyen H. A., Denis O., Vergison A., Tulkens P. M., Struelens M. J., Van Bambeke F., Intracellular Activity of Antibiotics in a Model of Human THP-1 Macrophages Infected by a Staphylococcus aureus Small-Colony Variant Strain Isolated from a Cystic Fibrosis Patient: Study of Antibiotic Combinations, 10.1128/aac.01146-08
- Clinical and Laboratory Standard Institute, CLSI document MS100-S23 (2013)
- Barcia-Macay M., Seral C., Mingeot-Leclercq M.-P., Tulkens P. M., Van Bambeke F., Pharmacodynamic Evaluation of the Intracellular Activities of Antibiotics against Staphylococcus aureus in a Model of THP-1 Macrophages, 10.1128/aac.50.3.841-851.2006
- Eliopoulos, Antibiotics in laboratory medicine, 330 (1996)
- Bonapace Charles R., Bosso John A., Friedrich Lawrence V., White Roger L., Comparison of methods of interpretation of checkerboard synergy testing, 10.1016/s0732-8893(02)00473-x
- Terminology relating to methods for the determination of susceptibility of bacteria to antimicrobial agents, 10.1046/j.1469-0691.2000.00149.x
- Desbiolles N., Piroth L., Lequeu C., Neuwirth C., Portier H., Chavanet P., Fractional Maximal Effect Method for In Vitro Synergy between Amoxicillin and Ceftriaxone and between Vancomycin and Ceftriaxone against Enterococcus faecalis and Penicillin-Resistant Streptococcus pneumoniae, 10.1128/aac.45.12.3328-3333.2001
- Li R C, Schentag J J, Nix D E, The fractional maximal effect method: a new way to characterize the effect of antibiotic combinations and other nonlinear pharmacodynamic interactions., 10.1128/aac.37.3.523
- Hauser, Infect Immun, 66, 1413 (1998)
- Tamma P. D., Cosgrove S. E., Maragakis L. L., Combination Therapy for Treatment of Infections with Gram-Negative Bacteria, 10.1128/cmr.05041-11
- Fleiszig S. M. J., Arora S. K., Van R., Ramphal R., FlhA, a Component of the Flagellum Assembly Apparatus of Pseudomonas aeruginosa, Plays a Role in Internalization by Corneal Epithelial Cells, 10.1128/iai.69.8.4931-4937.2001
- Plotkowski, Infect Immun, 62, 5456 (1994)
- Kondo Akira, Hirakata Yoichi, Gotoh Naomasa, Fukushima Kazuko, Yanagihara Katsunori, Ohno Hideaki, Higashiyama Yasuhito, Miyazaki Yoshitugu, Nishide Kiyoharu, Node Manabu, Yamada Yasuaki, Kohno Shigeru, Kamihira Shimeru, Quorum Sensing System Lactones Do Not Increase Invasiveness of a MexAB-OprM Efflux Mutant but Do Play a Partial Role inPseudomonas aeruginosaInvasion, 10.1111/j.1348-0421.2006.tb03806.x
- Hirakata Yoichi, Srikumar Ramakrishnan, Poole Keith, Gotoh Naomasa, Suematsu Takashi, Kohno Shigeru, Kamihira Shimeru, Hancock Robert E. W., Speert David P., Multidrug Efflux Systems Play an Important Role in the Invasiveness ofPseudomonas aeruginosa, 10.1084/jem.20020005
- McClure Carol D., Schiller Neal L., Inhibition of Macrophage Phagocytosis by Pseudomonas aeruginosa Rhamnolipids In Vitro and In Vivo, 10.1007/s002849900084
- Garcia-Medina R., Dunne W. M., Singh P. K., Brody S. L., Pseudomonas aeruginosa Acquires Biofilm-Like Properties within Airway Epithelial Cells, 10.1128/iai.73.12.8298-8305.2005
- Vallet Coralie M., Marquez Béatrice, Ngabirano Eva, Lemaire Sandrine, Mingeot-Leclercq Marie-Paule, Tulkens Paul M., Van Bambeke Françoise, Cellular accumulation of fluoroquinolones is not predictive of their intracellular activity: studies with gemifloxacin, moxifloxacin and ciprofloxacin in a pharmacokinetic/pharmacodynamic model of uninfected and infected macrophages, 10.1016/j.ijantimicag.2011.05.011
- Baudoux P., Bles N., Lemaire S., Mingeot-Leclercq M.-P., Tulkens P. M., Van Bambeke F., Combined effect of pH and concentration on the activities of gentamicin and oxacillin against Staphylococcus aureus in pharmacodynamic models of extracellular and intracellular infections, 10.1093/jac/dkl489
- Michael Julia, Barth Aline, Kloft Charlotte, Derendorf Hartmut, Pharmacodynamic In Vitro Models to Determine the Effect of Antibiotics, Fundamentals of Antimicrobial Pharmacokinetics and Pharmacodynamics (2014) ISBN:9780387756127 p.81-112, 10.1007/978-0-387-75613-4_5
- Hsieh Michael H., Yu Chen M., Yu Victor L., Chow Joseph W., Synergy assessed by checkerboard a critical analysis, 10.1016/0732-8893(93)90087-n
- Traugott Kristi A, Echevarria Kelly, Maxwell Pamela, Green Kay, Lewis James S, Monotherapy or Combination Therapy? ThePseudomonas aeruginosaConundrum, 10.1592/phco.31.6.598
- Bonapace Charles R, White Roger L, Friedrich Lawrence V, Bosso John A, Evaluation of antibiotic synergy against Acinetobacter baumannii: a comparison with Etest, time-kill, and checkerboard methods, 10.1016/s0732-8893(00)00163-2
- White, Antimicrob Agents Chemother, 40, 1914 (1996)
- Horrevorts A. M., de Ridder C. M., Poot M. C., de Jonge M. J. A., Degener J. E., Dzoljic-Danilovic G., Michel M. F., Kerrebijn K. F., Chequerboard titrations: the influence of the composition of serial dilutions of antibiotics on the fractional inhibitory concentration index and fractional bactericidal concentration index, 10.1093/jac/19.1.119
- Saiman Lisa, Clinical utility of synergy testing for multidrug-resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis: ‘the motion for’, 10.1016/j.prrv.2007.04.006
- BERENBAUM MORRIS C., Minor synergy and antagonism may be clinically important, 10.1093/jac/19.2.271
- Mackay M.L, Milne K, Gould I.M, Comparison of methods for assessing synergic antibiotic interactions, 10.1016/s0924-8579(00)00149-7
- Chandrasekar P. H., Crane L. R., Bailey E. J., Comparison of the activity of antibiotic combinations in vitro with clinical outcome and resistance emergence in serious infection by Pseudomonas aeruginosa in non-neutropenic patients, 10.1093/jac/19.3.321
- Visalli, Antimicrob Agents Chemother, 42, 953 (1998)
- Eliopoulos G M, Eliopoulos C T, Antibiotic combinations: should they be tested?, 10.1128/cmr.1.2.139
- Vidaillac C., Benichou L., Duval R. E., In Vitro Synergy of Colistin Combinations against Colistin-Resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae Isolates, 10.1128/aac.05996-11
- Cappelletty, Antimicrob Agents Chemother, 40, 677 (1996)
- Kresken Michael, Körber-Irrgang Barbara, Läuffer Jörg, Decker-Burgard Sabine, Davies Todd, In vitro activities of ceftobiprole combined with amikacin or levofloxacin against Pseudomonas aeruginosa: evidence of a synergistic effect using time–kill methodology, 10.1016/j.ijantimicag.2011.01.028
- Meyer Richard D., Liu Susan, In vitro synergy studies with ciprofloxacin and selected beta-lactam agents and aminoglycosides against multidrug-resistant Pseudomonas aeruginosa, 10.1016/0732-8893(88)90017-x
- He Wendy, Kaniga Koné, Lynch A. Simon, Flamm Robert K., Davies Todd A., In vitro Etest synergy of doripenem with amikacin, colistin, and levofloxacin against Pseudomonas aeruginosa with defined carbapenem resistance mechanisms as determined by the Etest method, 10.1016/j.diagmicrobio.2012.08.014
- Pankuch G. A., Lin G., Seifert H., Appelbaum P. C., Activity of Meropenem with and without Ciprofloxacin and Colistin against Pseudomonas aeruginosa and Acinetobacter baumannii, 10.1128/aac.00689-07
- Burgess David S, Nathisuwan Surakit, Cefepime, piperacillin/tazobactam, gentamicin, ciprofloxacin, and levofloxacin alone and in combination against Pseudomonas aeruginosa, 10.1016/s0732-8893(02)00420-0
Bibliographic reference |
Buyck, Julien ; Tulkens, Paul M. ; Van Bambeke, Françoise. Activities of antibiotic combinations against resistant strains of Pseudomonas aeruginosa in a model of infected THP-1 monocytes. In: Antimicrobial Agents and Chemotherapy, Vol. 59, no. 1, p. 258-268 (2015) |
Permanent URL |
http://hdl.handle.net/2078.1/153978 |